Articles tagged with: Velcade
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in …
A new retrospective study by Emory University researchers may stir debate about the best way to treat high-risk myeloma patients.
The researchers investigated treating high-risk myeloma patients for up to three years with a combination of Revlimid, Velcade, and dexamethasone.
The extended three-drug therapy, which the authors describe as a combined consolidation/maintenance regimen, was initiated after the patients had received a stem cell transplant. The patients’ transplants were carried out soon after completion of the first (induction) treatment regimen following diagnosis.
Some, but not all, of the patients also received …
Researchers from the U.S. National Cancer Institute recently initiated a Phase 1 clinical trial that will test whether dinaciclib in combination with Velcade and dexamethasone is safe and effective as an anti-myeloma therapy.
The clinical trial is taking place at a several locations across the United States, and is open to multiple myeloma patients who have relapsed after at least one previous myeloma treatment regimen.
Dinaciclib (SCH727965) is currently being developed by Merck (NYSE: MRK). It is a small molecule that inhibits enzymes called cyclin-dependent kinases, which regulate the cell cycle and are often overactive in cancer cells. Dinaciclib interrupts the cell cycle by inhibiting these kinases, ultimately causing the cell to die.
Preclinical studies have shown that Velcade (bortezomib) is more effective when cyclin-dependent kinases are inhibited, and a previous Phase 1/2 study showed that dinaciclib is safe and active as a monotherapy for relapsed/refractory myeloma (see related Beacon news).
Therefore, this study is being conducted to determine the efficacy and safety of dinaciclib in combination with Velcade and dexamethasone (Decadron).
For more information about the trial, see the trial description at the U.S. clinical trial registry.
Results of a recent international Phase 3 study demonstrate that the addition of Zolinza to Velcade increases response rates and slightly improves progression-free survival in relapsed and refractory myeloma patients compared to treatment with Velcade alone.
However, despite improvements in responses, the difference in progression-free survival between the two treatment groups was small. Treatment with Zolinza plus Velcade was associated with …
Patients With Periodontitis May Be At Increased Risk For Developing Osteonecrosis Of The Jaw – Results from a small Australian trial suggest that multiple myeloma patients who receive bisphosphonates and experience periodontitis (inflammation or bleeding in their gums) may be at an increased risk for developing osteonecrosis of the jaw. Osteonecrosis of the jaw is a condition that is associated with a loss of blood supply to the jaw, causing the jawbone tissue to die. It can occur in multiple myeloma patients during treatment with bisphosphonates, such as Aredia (pamidronate) and Zometa (zoledronic acid). Specifically, the researchers found that patients with at least one spot in their gums with periodontitis with a depth greater than 4 mm were at a particularly high risk of developing jawbone disease. For more information, please refer to the study in the Journal of Oral and Maxillofacial Surgery (abstract).
Blood Test May Predict Velcade-Induced Peripheral Neuropathy – Findings from a prospective Japanese trial involving more than 60 patients indicate that a blood test may be able to predict whether a multiple myeloma patient will develop peripheral neuropathy (pain, tingling, and loss of sensation in the extremities) when treated with Velcade (bortezomib). The Japanese researchers took samples of each trial participant’s blood before the patients started treatment with Velcade. The cells in the blood samples were then stimulated to see how much they started to produce certain immune system proteins. The investigators found that, when stimulated, the blood from patients who did not develop peripheral neuropathy during Velcade treatment was significantly more likely to start producing the protein interleukin 2 (IL-2) than the blood from patients who developed peripheral neuropathy. IL-2 stimulates the production of certain types of white blood cells, known as lymphocytes, which defend the body against infections and other threats. Based on their results, the researchers recommend that the blood test they used be validated in additional studies with larger numbers of patients. For more information, please refer to the article in the Blood Cancer Journal (full text, open access).
Phase 2 Trial To Study LCL161 In Relapsed and Refractory Multiple Myeloma Patients – The Mayo Clinic will soon be opening for enrollment a Phase 2 trial of the investigational compound LCL161, alone or in combination with cyclophosphamide (Cytoxan), in relapsed and refractory multiple myeloma patients. LCL161, which is being developed by the pharmaceutical company Novartis, works by binding to, and thereby neutralizing, inhibitor apoptosis proteins (IAPs), which shield cancer cells from cell death. The compound is also being investigated as a treatment for a number of different solid-tumor cancers. For more information on the trial, please see the clinical trial description.